Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate
The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.
You may also be interested in...
While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space.
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.